129 related articles for article (PubMed ID: 7531365)
1. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases.
Uckun FM; Evans WE; Forsyth CJ; Waddick KG; Ahlgren LT; Chelstrom LM; Burkhardt A; Bolen J; Myers DE
Science; 1995 Feb; 267(5199):886-91. PubMed ID: 7531365
[TBL] [Abstract][Full Text] [Related]
2. Membrane-associated CD19-LYN complex is an endogenous p53-independent and Bc1-2-independent regulator of apoptosis in human B-lineage lymphoma cells.
Myers DE; Jun X; Waddick KG; Forsyth C; Chelstrom LM; Gunther RL; Tumer NE; Bolen J; Uckun FM
Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9575-9. PubMed ID: 7568175
[TBL] [Abstract][Full Text] [Related]
3. Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.
Gunther R; Chelstrom LM; Tuel-Ahlgren L; Simon J; Myers DE; Uckun FM
Blood; 1995 May; 85(9):2537-45. PubMed ID: 7537120
[TBL] [Abstract][Full Text] [Related]
4. Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide.
Uckun FM; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Manivel C; Irvin JD; Myers DE; Gunther R
Blood; 1992 Jun; 79(12):3116-29. PubMed ID: 1375841
[TBL] [Abstract][Full Text] [Related]
5. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
Jansen B; Kersey JH; Jaszcz WB; Gunther R; Nguyen DP; Chelstrom LM; Tuel-Ahlgren L; Uckun FM
Leukemia; 1993 Feb; 7(2):290-7. PubMed ID: 7678881
[TBL] [Abstract][Full Text] [Related]
6. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor.
Uckun FM; Messinger Y; Chen CL; O'Neill K; Myers DE; Goldman F; Hurvitz C; Casper JT; Levine A
Clin Cancer Res; 1999 Dec; 5(12):3906-13. PubMed ID: 10632319
[TBL] [Abstract][Full Text] [Related]
7. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency.
Uckun FM; Manivel C; Arthur D; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Gunther R
Blood; 1992 May; 79(9):2201-14. PubMed ID: 1373967
[TBL] [Abstract][Full Text] [Related]
8. In vivo toxicity and pharmacokinetic features of B43 (anti-CD19)-genistein immunoconjugate in nonhuman primates.
Messinger Y; Yanishevski Y; Ek O; Zeren T; Waurzyniak B; Gunther R; Chelstrom L; Chandan-Langlie M; Schneider E; Myers DE; Evans W; Uckun FM
Clin Cancer Res; 1998 Jan; 4(1):165-70. PubMed ID: 9516966
[TBL] [Abstract][Full Text] [Related]
9. Large scale manufacturing of B43(anti-CD19)-genistein for clinical trials in leukemia and lymphoma.
Myers DE; Sicheneder A; Clementson D; Dvorak N; Venkatachalam T; Sev AR; Chandan-Langlie M; Uckun FM
Leuk Lymphoma; 1998 Apr; 29(3-4):329-38. PubMed ID: 9684930
[TBL] [Abstract][Full Text] [Related]
10. Engagement of the CD19 receptor on human B-lineage leukemia cells activates LCK tyrosine kinase and facilitates radiation-induced apoptosis.
Waddick KG; Chae HP; Tuel-Ahlgren L; Jarvis LJ; Dibirdik I; Myers DE; Uckun FM
Radiat Res; 1993 Dec; 136(3):313-9. PubMed ID: 7506428
[TBL] [Abstract][Full Text] [Related]
11. In vivo toxicity and pharmacokinetic features of B43(Anti-CD19)-Genistein immunoconjugate.
Ek O; Yanishevski Y; Zeren T; Waurzyniak B; Gunther R; Chelstrom L; Chandan-Langlie M; Schneider E; Myers DE; Evans W; Uckun FM
Leuk Lymphoma; 1998 Jul; 30(3-4):389-94. PubMed ID: 9713969
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in patients with B-lineage lymphoid malignancies.
Chen CL; Levine A; Rao A; O'Neill K; Messinger Y; Myers DE; Goldman F; Hurvitz C; Casper JT; Uckun FM
J Clin Pharmacol; 1999 Dec; 39(12):1248-55. PubMed ID: 10586390
[TBL] [Abstract][Full Text] [Related]
13. CD40 signaling pathway: anti-CD40 monoclonal antibody induces rapid dephosphorylation and phosphorylation of tyrosine-phosphorylated proteins including protein tyrosine kinase Lyn, Fyn, and Syk and the appearance of a 28-kD tyrosine phosphorylated protein.
Faris M; Gaskin F; Parsons JT; Fu SM
J Exp Med; 1994 Jun; 179(6):1923-31. PubMed ID: 7515102
[TBL] [Abstract][Full Text] [Related]
14. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemia.
Uckun FM; Chelstrom LM; Irvin JD; Finnegan D; Gunther R; Young J; Kuebelbeck V; Myers DE; Houston LL
Blood; 1992 May; 79(10):2649-61. PubMed ID: 1375109
[TBL] [Abstract][Full Text] [Related]
15. Effects of the intermolecular toxin-monoclonal antibody linkage on the in vivo stability, immunogenicity and anti-leukemic activity of B43 (anti-CD19) pokeweed antiviral protein immunotoxin.
Uckun FM; Myers DE; Irvin JD; Kuebelbeck VM; Finnegan D; Chelstrom LM; Houston LL
Leuk Lymphoma; 1993 Apr; 9(6):459-76. PubMed ID: 7687916
[TBL] [Abstract][Full Text] [Related]
16. CD19-antigen specific nanoscale liposomal formulation of a SYK P-site inhibitor causes apoptotic destruction of human B-precursor leukemia cells.
Myers DE; Yiv S; Qazi S; Ma H; Cely I; Shahidzadeh A; Arellano M; Finestone E; Gaynon PS; Termuhlen A; Cheng J; Uckun FM
Integr Biol (Camb); 2014 Aug; 6(8):766-80. PubMed ID: 24910947
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a human t(4;11) leukemia in severe combined immunodeficient mice and successful treatment using anti-CD19 (B43)-pokeweed antiviral protein immunotoxin.
Jansen B; Uckun FM; Jaszcz WB; Kersey JH
Cancer Res; 1992 Jan; 52(2):406-12. PubMed ID: 1370213
[TBL] [Abstract][Full Text] [Related]
18. Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins.
Herrera L; Yarbrough S; Ghetie V; Aquino DB; Vitetta ES
Leukemia; 2003 Feb; 17(2):334-8. PubMed ID: 12592332
[TBL] [Abstract][Full Text] [Related]
19. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency.
Gunther R; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Uckun FM
Leukemia; 1993 Feb; 7(2):298-309. PubMed ID: 7678882
[TBL] [Abstract][Full Text] [Related]
20. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H
Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
